AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
adapalene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 87 | 106685-40-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.21 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 0 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EGFR,EIF2AK3,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,STK33,TEK,TGFBR1,TTK | 34 | |||
| kinase-selectivity-class | EIF2AK3,PDK4 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 31, 1996 | FDA | GALDERMA LABS LP |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Skin burning sensation | 779.98 | 32.16 | 170 | 2866 | 19441 | 90605970 |
| Erythema | 485.92 | 32.16 | 206 | 2830 | 229040 | 90396371 |
| Dry skin | 449.86 | 32.16 | 151 | 2885 | 87922 | 90537489 |
| Skin exfoliation | 340.53 | 32.16 | 115 | 2921 | 67798 | 90557613 |
| Skin irritation | 329.76 | 32.16 | 79 | 2957 | 13524 | 90611887 |
| Pain of skin | 281.84 | 32.16 | 72 | 2964 | 16010 | 90609401 |
| Chemical burn of skin | 110.55 | 32.16 | 16 | 3020 | 160 | 90625251 |
| Inappropriate schedule of product administration | 107.05 | 32.16 | 65 | 2971 | 149868 | 90475543 |
| Skin swelling | 98.23 | 32.16 | 26 | 3010 | 6588 | 90618823 |
| Acne | 71.07 | 32.16 | 29 | 3007 | 28478 | 90596933 |
| Pruritus | 62.06 | 32.16 | 83 | 2953 | 541442 | 90083969 |
| Overdose | 56.94 | 32.16 | 45 | 2991 | 157664 | 90467747 |
| Dermatitis | 53.32 | 32.16 | 22 | 3014 | 22198 | 90603213 |
| Swelling face | 52.18 | 32.16 | 33 | 3003 | 81319 | 90544092 |
| Rash macular | 49.88 | 32.16 | 23 | 3013 | 30257 | 90595154 |
| Rash | 40.77 | 32.16 | 85 | 2951 | 796015 | 89829396 |
| Rash papular | 38.40 | 32.16 | 17 | 3019 | 20338 | 90605073 |
| Skin fissures | 38.04 | 32.16 | 17 | 3019 | 20792 | 90604619 |
| Chemical burn | 35.07 | 32.16 | 7 | 3029 | 508 | 90624903 |
| Urticaria | 32.74 | 32.16 | 46 | 2990 | 312688 | 90312723 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Skin burning sensation | 209.18 | 65.79 | 42 | 585 | 7445 | 42613263 |
| Erythema | 207.78 | 65.79 | 72 | 555 | 108721 | 42511987 |
| Dry skin | 156.73 | 65.79 | 48 | 579 | 48290 | 42572418 |
| Skin exfoliation | 112.36 | 65.79 | 36 | 591 | 41517 | 42579191 |
| Skin irritation | 79.04 | 65.79 | 19 | 608 | 7555 | 42613153 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Skin burning sensation | 926.11 | 39.36 | 194 | 2968 | 21631 | 110564506 |
| Erythema | 611.19 | 39.36 | 248 | 2914 | 291199 | 110294938 |
| Dry skin | 560.49 | 39.36 | 180 | 2982 | 107473 | 110478664 |
| Skin exfoliation | 428.75 | 39.36 | 140 | 3022 | 87511 | 110498626 |
| Skin irritation | 374.78 | 39.36 | 88 | 3074 | 16231 | 110569906 |
| Pain of skin | 321.71 | 39.36 | 81 | 3081 | 19948 | 110566189 |
| Chemical burn of skin | 132.72 | 39.36 | 19 | 3143 | 208 | 110585929 |
| Inappropriate schedule of product administration | 123.27 | 39.36 | 75 | 3087 | 203562 | 110382575 |
| Skin swelling | 106.68 | 39.36 | 28 | 3134 | 8052 | 110578085 |
| Pruritus | 81.19 | 39.36 | 91 | 3071 | 581469 | 110004668 |
| Acne | 77.87 | 39.36 | 31 | 3131 | 33489 | 110552648 |
| Dermatitis | 69.06 | 39.36 | 27 | 3135 | 27810 | 110558327 |
| Rash macular | 66.96 | 39.36 | 29 | 3133 | 38657 | 110547480 |
| Overdose | 63.76 | 39.36 | 53 | 3109 | 233741 | 110352396 |
| Acne cystic | 61.63 | 39.36 | 12 | 3150 | 900 | 110585237 |
| Urticaria | 53.30 | 39.36 | 55 | 3107 | 318802 | 110267335 |
| Swelling face | 50.62 | 39.36 | 32 | 3130 | 92289 | 110493848 |
| Rash papular | 48.73 | 39.36 | 21 | 3141 | 27618 | 110558519 |
| Rash | 45.87 | 39.36 | 83 | 3079 | 820881 | 109765256 |
| Sensitive skin | 44.86 | 39.36 | 12 | 3150 | 3700 | 110582437 |
| Hypersensitivity | 42.68 | 39.36 | 55 | 3107 | 403943 | 110182194 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D10AD03 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne |
| ATC | D10AD53 | DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Retinoids for topical use in acne |
| FDA CS | M0018962 | Retinoids |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| FDA EPC | N0000175607 | Retinoid |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:82665 | EC 2.7.11.22 (cyclin-dependent kinase) inhibitor |
Related Drugs by ATC class:
D10AD Retinoids for topical use in acne 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acne vulgaris | indication | 88616000 | |
| Photosensitivity | contraindication | 90128006 | |
| Erythroderma | contraindication | 399992009 | |
| Inflammatory dermatosis | contraindication | 703938007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.92 | acidic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.1% | DIFFERIN | GALDERMA LABS LP | N022502 | March 17, 2010 | DISCN | LOTION | TOPICAL | 8435502 | Sept. 15, 2026 | TREATMENT OF ACNE |
| 0.1% | DIFFERIN | GALDERMA LABS LP | N022502 | March 17, 2010 | DISCN | LOTION | TOPICAL | 8709392 | Sept. 15, 2026 | TREATMENT OF ACNE |
| 0.1%;2.5% | EPIDUO | GALDERMA LABS LP | N022320 | Dec. 8, 2008 | DISCN | GEL | TOPICAL | 8071644 | July 18, 2027 | TREATMENT OF ACNE |
| 0.1%;2.5% | EPIDUO | GALDERMA LABS LP | N022320 | Dec. 8, 2008 | DISCN | GEL | TOPICAL | 8080537 | July 18, 2027 | TREATMENT OF ACNE |
| 0.1%;2.5% | EPIDUO | GALDERMA LABS LP | N022320 | Dec. 8, 2008 | DISCN | GEL | TOPICAL | 8129362 | July 18, 2027 | TREATMENT OF ACNE |
| 0.1% | DIFFERIN | GALDERMA LABS LP | N022502 | March 17, 2010 | DISCN | LOTION | TOPICAL | 7998467 | May 31, 2028 | TREATMENT OF ACNE |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 10220049 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 10624918 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 9561208 | June 3, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 8288434 | Aug. 5, 2029 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 12128059 | July 31, 2040 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | 11389467 | Dec. 28, 2040 | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.15%;3.1%;1.2% | CABTREO | BAUSCH | N216632 | Oct. 20, 2023 | RX | GEL | TOPICAL | Oct. 20, 2026 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Retinoic acid receptor beta | Nuclear hormone receptor | AGONIST | Ki | 7.47 | CHEMBL | CHEMBL | |||
| Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | Ki | 6.89 | CHEMBL | CHEMBL | |||
| Glycine receptor subunit alpha-1 | Ion channel | EC50 | 5.89 | CHEMBL | |||||
| Retinoic acid receptor alpha | Nuclear hormone receptor | Ki | 5.96 | CHEMBL | |||||
| Aspartate aminotransferase, cytoplasmic | Enzyme | IC50 | 4.66 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020981 | VUID |
| N0000148452 | NUI |
| D01112 | KEGG_DRUG |
| 153184 | RXNORM |
| C0165631 | UMLSCUI |
| CHEBI:31174 | CHEBI |
| CHEMBL1265 | ChEMBL_ID |
| D000068816 | MESH_DESCRIPTOR_UI |
| DB00210 | DRUGBANK_ID |
| 60164 | PUBCHEM_CID |
| 5429 | IUPHAR_LIGAND_ID |
| 6675 | INN_ID |
| 1L4806J2QF | UNII |
| 173193 | MMSL |
| 4134 | MMSL |
| 6162 | MMSL |
| 4020981 | VANDF |
| 005905 | NDDF |
| 108903004 | SNOMEDCT_US |
| 386934008 | SNOMEDCT_US |
| 1L4806J2QF | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0424 | CREAM | 1 mg | TOPICAL | ANDA | 23 sections |
| Cabtreo | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0187-0006 | GEL | 1.50 mg | TOPICAL | NDA | 26 sections |
| Differin Epiduo | HUMAN OTC DRUG LABEL | 2 | 0299-4908 | GEL | 1 mg | TOPICAL | NDA | 15 sections |
| Differin | HUMAN OTC DRUG LABEL | 1 | 0299-4910 | GEL | 1 mg | TOPICAL | NDA | 14 sections |
| epiduo forte | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0299-5906 | GEL | 3 mg | TOPICAL | NDA | 24 sections |
| DIFFERIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0299-5918 | GEL | 3 mg | TOPICAL | NDA | 25 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0143 | GEL | 1 mg | TOPICAL | ANDA | 15 sections |
| PanOxyl | HUMAN OTC DRUG LABEL | 1 | 0316-0284 | GEL | 1 mg | TOPICAL | ANDA | 15 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 0363-0888 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 0363-1401 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 0363-4110 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0472-0126 | GEL | 3 mg | TOPICAL | ANDA | 17 sections |
| Adapalene and benzoyl peroxide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0480-3154 | GEL | 3 mg | TOPICAL | ANDA | 23 sections |
| ADAPALENE | HUMAN OTC DRUG LABEL | 1 | 0536-1412 | GEL | 1 mg | TOPICAL | ANDA | 15 sections |
| Proactiv MD AdapaleneAcne Treatment | HUMAN OTC DRUG LABEL | 1 | 11410-958 | GEL | 0.10 g | TOPICAL | ANDA | 15 sections |
| ADAPALENE | HUMAN OTC DRUG LABEL | 1 | 11822-0062 | GEL | 1 mg | TOPICAL | ANDA | 15 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 21130-754 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene Gel USP, 0.3% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21922-051 | GEL | 3 mg | TOPICAL | ANDA | 25 sections |
| Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21922-052 | GEL | 1 mg | TOPICAL | ANDA | 25 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 30142-725 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 36800-088 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 41250-288 | GEL | 1 mg | TOPICAL | ANDA | 14 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42546-720 | GEL | 45 g | TOPICAL | ANDA | 20 sections |
| Adapalene | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-453 | CREAM | 0.10 g | TOPICAL | NDA authorized generic | 24 sections |
| adapalene and benzoyl peroxide | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-846 | GEL | 0.10 g | TOPICAL | ANDA | 25 sections |
| ADAPALENE AND BENZOYL PEROXIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 45802-853 | GEL | 3 mg | TOPICAL | ANDA | 24 sections |
| Adapalene | HUMAN OTC DRUG LABEL | 1 | 46122-768 | GEL | 1 mg | TOPICAL | ANDA | 15 sections |
| ADAPALENE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 46708-549 | GEL | 3 mg | TOPICAL | ANDA | 17 sections |
| ADAPALENE AND BENZOYL PEROXIDE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 46708-662 | GEL | 3 mg | TOPICAL | ANDA | 22 sections |
| Adapalene Topical Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49908-117 | SOLUTION | 1 mg | TOPICAL | ANDA | 19 sections |